Racial and Ethnic Reporting and Representation in US Alzheimer Clinical Trials
US-based phase 3 AD trials showed substantial gaps in racial and ethnic reporting and representation from 1997 to 2023, limiting the evaluation of treatment safety and efficacy across diverse populations. These findings suggest that stronger reporting standards and more inclusive trial design and recruitment strategies are needed to improve the equity and generalizability of AD trials.
Authors
- Zhuoer Lin (ORCID: https://orcid.org/0000-0003-3937-2293)
- Joseph S. Ross (ORCID: https://orcid.org/0000-0002-9218-3320)
- K. H. Vincent Lau (ORCID: https://orcid.org/0000-0003-1416-5589)
- Ruochen Sun
- Maggie Chen (ORCID: https://orcid.org/0000-0001-6573-4134)
- Sophia Stumpf
Institutions
- University of Illinois Urbana-Champaign (US)
- Yale University (US)
- University of Illinois Chicago (US)
- Yale New Haven Health System (US)
- University of Pennsylvania (US)
Publication Details
- Journal
- JAMA Network Open
- Published
- 2026-03-27
- DOI
- https://doi.org/10.1001/jamanetworkopen.2026.2427
- Citations
- 1
- Primary Topic
- Ethics in Clinical Research
- Type
- article
- Field-Weighted Citation Impact
- 41.85